{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:09:10Z","timestamp":1787400550158,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Sanofi"],"award-info":[{"award-number":["Sanofi"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease is a rare, X-linked inherited lysosomal storage disorder, that manifests as a heterogeneous disease with renal, cardiac and nervous system involvement. The most common pain experienced by people with Fabry disease are episodes of neuropathic pain reported in up to 80% of classical hemizygous male patients and up to 65% of heterozygous female patients. No clear consensus exists within UK clinical practice for the assessment and management of pain in Fabry disease based on agreed clinical practice and clinical experience. Here we describe a modified Delphi initiative to establish expert consensus on management of pain in Fabry disease in the UK clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Delphi panel members were identified based on their demonstrated expertise in managing adult or paediatric patients with Fabry disease in the UK and recruited by an independent third-party administrator. Ten expert panellists agreed to participate in two survey rounds, during which they remained anonymous to each other. Circulation of the questionnaires, and collection and processing of the panel\u2019s responses were conducted between September 2021 and December 2021. All questions required an answer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Delphi panel reached a consensus on 21 out of 41 aspects of pain assessment and management of pain in Fabry disease. These encompassed steps in the care pathway from the goals of therapy through to holistic support, including the use of gabapentin and carbamazepine as first-line analgesic medications for the treatment of neuropathic pain in Fabry disease, as well as the proactive management of symptoms of anxiety and\/or depression associated with Fabry pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The consensus panel outcomes reported here have highlighted strengths in current UK clinical practice, along with unmet needs for further research and agreement. This consensus is intended to prompt the next steps towards developing clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02796-1","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:02:01Z","timestamp":1689926521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-6332","authenticated-orcid":false,"given":"Karolina M.","family":"Stepien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Broomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Deegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Forshaw-Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry\u2019s Disease \u2014 Ceramidetrihexosidase Deficiency. New Engl J Medicine. 1967;276:1163\u20137.","journal-title":"New Engl J Medicine"},{"key":"2796_CR2","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"2796_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236\u201342.","journal-title":"Eur J Clin Invest"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N \u00dc\u00e7eyler","year":"2014","unstructured":"\u00dc\u00e7eyler N, Ganendiran S, Kramer D, Sommer C. Characterization of Pain in Fabry Disease. Clin J Pain. 2014;30:915\u201320.","journal-title":"Clin J Pain"},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86\u201392.","journal-title":"Acta Paediatr"},{"key":"2796_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry Disease in 352 Pediatric patients in the Fabry Registry. Pediatr Res. 2008;64:550\u20135.","journal-title":"Pediatr Res"},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41:141\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00000446-200104000-00019","volume":"101","author":"VL Stryker","year":"2001","unstructured":"Stryker VL, Kreps C. Fabry Disease. Am J Nurs. 2001;101:39\u201344.","journal-title":"Am J Nurs"},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A, et al. Nature and Prevalence of Pain in Fabry Disease and its response to enzyme replacement Therapy\u2014A retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23:535\u201342.","journal-title":"Clin J Pain"},{"key":"2796_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ncpneuro0407","volume":"3","author":"AT M\u00f8ller","year":"2007","unstructured":"M\u00f8ller AT, Jensen TS. Neurological manifestations in Fabry\u2019s disease. Nat Clin Pract Neuro. 2007;3:95\u2013106.","journal-title":"Nat Clin Pract Neuro"},{"key":"2796_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Brys M, Marthol H, Stemper B, D\u00fctsch M. Enzyme replacement therapy improves function of C-, adelta- and abeta-nerve fibers in Fabry neuropathy. Neurology. 2004;62:1066\u201372.","journal-title":"Neurology"},{"key":"2796_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","volume":"106","author":"M Biegstraaten","year":"2012","unstructured":"Biegstraaten M, Hollak CEM, Bakkers M, Faber CG, Aerts JMFG, van Schaik IN. Small fiber neuropathy in Fabry disease. Mol Genet Metab. 2012;106:135\u201341.","journal-title":"Mol Genet Metab"},{"key":"2796_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","volume":"594","author":"L Choi","year":"2015","unstructured":"Choi L, Vernon J, Kopach O, Minett MS, Mills K, Clayton PT, et al. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett. 2015;594:163\u20138.","journal-title":"Neurosci Lett"},{"key":"2796_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1651-2227.2002.tb03108.x","volume":"91","author":"M Hilz","year":"2002","unstructured":"Hilz M. Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr. 2002;91:38\u201342.","journal-title":"Acta Paediatr"},{"key":"2796_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2377-13-47","volume":"13","author":"N \u00dc\u00e7eyler","year":"2013","unstructured":"\u00dc\u00e7eyler N, Kahn A-K, Kramer D, Zeller D, Casanova-Molla J, Wanner C, et al. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case\u2013control study. BMC Neurol. 2013;13:47\u20137.","journal-title":"BMC Neurol"},{"key":"2796_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.21606","volume":"41","author":"R Liguori","year":"2010","unstructured":"Liguori R, Stasi VD, Bugiardini E, Mignani R, Burlina A, Borsini W, et al. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve. 2010;41:409\u201312.","journal-title":"Muscle Nerve"},{"key":"2796_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2377-11-61","volume":"11","author":"AP Burlina","year":"2011","unstructured":"Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.","journal-title":"BMC Neurol"},{"key":"2796_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fnins.2020.00448","volume":"14","author":"J Forstenpointner","year":"2020","unstructured":"Forstenpointner J, Sendel M, Moeller P, Reimer M, Canaan-K\u00fchl S, Gaedeke J, et al. Bridging the gap between vessels and nerves in Fabry Disease. Front Neurosci-Switz. 2020;14:448.","journal-title":"Front Neurosci-Switz"},{"key":"2796_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fneur.2017.00335","volume":"8","author":"B Namer","year":"2017","unstructured":"Namer B, \u00d8rstavik K, Schmidt R, Mair N, Kleggetveit IP, Zeidler M, et al. Changes in ionic conductance signature of nociceptive neurons underlying Fabry Disease phenotype. Front Neurol. 2017;8:335.","journal-title":"Front Neurol"},{"key":"2796_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1529-8027.2012.00438.x","volume":"17","author":"N Geevasinga","year":"2012","unstructured":"Geevasinga N, Tchan M, Sillence D, Vucic S. Upregulation of inward rectifying currents and Fabry disease neuropathy. J Peripher Nerv Syst. 2012;17:399\u2013406.","journal-title":"J Peripher Nerv Syst"},{"key":"2796_CR22","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.3390\/jcm10184168","volume":"10","author":"JN Rajan","year":"2021","unstructured":"Rajan JN, Ireland K, Johnson R, Stepien KM. Review of mechanisms, Pharmacological Management, Psychosocial Implications, and holistic treatment of Pain in Fabry Disease. J Clin Med. 2021;10:4168.","journal-title":"J Clin Med"},{"key":"2796_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cge.12673","volume":"89","author":"J Politei","year":"2015","unstructured":"Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand C, et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet. 2015;89:5\u20139.","journal-title":"Clin Genet"},{"key":"2796_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry Disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22:568\u201376.","journal-title":"CNS Neurosci Ther"},{"key":"2796_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","volume":"16","author":"Y Schuller","year":"2016","unstructured":"Schuller Y, Linthorst GE, Hollak CEM, Schaik INV, Biegstraaten M. Pain management strategies for neuropathic pain in Fabry disease - a systematic review. BMC Neurol. 2016;16:25.","journal-title":"BMC Neurol"},{"key":"2796_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","volume":"8","author":"M Niederberger","year":"2020","unstructured":"Niederberger M, Spranger J. Delphi technique in Health Sciences: a map. Front Public Health. 2020;8:457.","journal-title":"Front Public Health"},{"key":"2796_CR27","doi-asserted-by":"publisher","first-page":"e035182","DOI":"10.1136\/bmjopen-2019-035182","volume":"10","author":"DA Hughes","year":"2020","unstructured":"Hughes DA, Aguiar P, Deegan PB, Ezgu F, Frustaci A, Lidove O, et al. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open. 2020;10:e035182.","journal-title":"BMJ Open"},{"key":"2796_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the european Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"key":"2796_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","volume":"114","author":"L van der Tol","year":"2015","unstructured":"van der Tol L, Svarstad E, Ortiz A, T\u00f8ndel C, Oliveira JP, Vogt L, et al. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Mol Genet Metab. 2015;114:242\u20137.","journal-title":"Mol Genet Metab"},{"key":"2796_CR30","doi-asserted-by":"crossref","unstructured":"Concolino D, Degennaro E, Parini R, group FD working, order) D working group list of collaborators (alphabetical, Antuzzi D et al. Delphi consensus on the current clinical and therapeutic knowledge on Anderson\u2013Fabry disease. Eur J Intern Med 2014; 25:751\u20136.","DOI":"10.1016\/j.ejim.2014.07.009"},{"key":"2796_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13023-021-01894-2","volume":"16","author":"A Hamed","year":"2021","unstructured":"Hamed A, DasMahapatra P, Lyn N, Gwaltney C, Hopkin RJ. Development of the Fabry Disease patient-reported outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease. Orphanet J Rare Dis. 2021;16:285.","journal-title":"Orphanet J Rare Dis"},{"key":"2796_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-10-116","volume":"10","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, et al. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ). Health Qual Life Out. 2012;10:116.","journal-title":"Health Qual Life Out"},{"key":"2796_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ajmg.b.32297","volume":"168","author":"N Bugescu","year":"2015","unstructured":"Bugescu N, Alioto A, Segal S, Cordova M, Packman W. The neurocognitive impact of Fabry disease on pediatric patients. Am J Medical Genetics Part B Neuropsychiatric Genetics. 2015;168:204\u201310.","journal-title":"Am J Medical Genetics Part B Neuropsychiatric Genetics"},{"key":"2796_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0333102409354389","volume":"30","author":"A Milde-Busch","year":"2009","unstructured":"Milde-Busch A, Heinrich S, Thomas S, K\u00fchnlein A, Radon K, Straube A, et al. Quality of life in adolescents with headache: results from a population-based survey. Cephalalgia. 2009;30:713\u201321.","journal-title":"Cephalalgia"},{"key":"2796_CR35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, Baldwin A, Dombi E, Toledo-Tamula MA, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social\u2010emotional functioning, and quality of life. Am J Med Genet. 2015;167:2103\u201313.","journal-title":"Am J Med Genet"},{"key":"2796_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1651-2227.2002.tb03109.x","volume":"91","author":"C Cleeland","year":"2002","unstructured":"Cleeland C. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr. 2002;91:43\u20137.","journal-title":"Acta Paediatr"},{"key":"2796_CR37","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jval.2011.05.002","volume":"14","author":"JTR Clarke","year":"2011","unstructured":"Clarke JTR, Giugliani R, Sunder-Plassmann G, Elliott PM, Pintos-Morell G, Hernberg-St\u00e5hl E, et al. Impact of measures to enhance the value of observational surveys in Rare Diseases: the Fabry Outcome Survey (FOS). Value Health. 2011;14:862\u20136.","journal-title":"Value Health"},{"key":"2796_CR38","doi-asserted-by":"publisher","first-page":"e11231","DOI":"10.2196\/11231","volume":"6","author":"SE Thurnheer","year":"2018","unstructured":"Thurnheer SE, Gravestock I, Pichierri G, Steurer J, Burgstaller JM. Benefits of mobile apps in Pain Management: systematic review. JMIR Mhealth Uhealth. 2018;6:e11231.","journal-title":"JMIR Mhealth Uhealth"},{"key":"2796_CR39","doi-asserted-by":"publisher","first-page":"113134","DOI":"10.1016\/j.expneurol.2019.113134","volume":"324","author":"V Rickert","year":"2020","unstructured":"Rickert V, Kramer D, Schubert A-L, Sommer C, Wischmeyer E, \u00dc\u00e7eyler N. Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. Exp Neurol. 2020;324:113134.","journal-title":"Exp Neurol"},{"key":"2796_CR40","doi-asserted-by":"publisher","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","volume":"14","author":"M Lenders","year":"2022","unstructured":"Lenders M, Brand E. Fabry disease \u2013 a multisystemic disease with gastrointestinal manifestations. Gut Microbes. 2022;14:2027852.","journal-title":"Gut Microbes"},{"key":"2796_CR41","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S, Investigators FOSE. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2796_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","volume":"146","author":"EP Halmos","year":"2014","unstructured":"Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A Diet Low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67\u201375e5.","journal-title":"Gastroenterology"},{"key":"2796_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clnesp.2020.09.020","volume":"40","author":"C Krieger-Gr\u00fcbel","year":"2020","unstructured":"Krieger-Gr\u00fcbel C, Hutter S, Hiestand M, Brenner I, G\u00fcsewell S, Borovicka J. Treatment efficacy of a low FODMAP diet compared to a low lactose diet in IBS patients: a randomized, cross-over designed study. Clin Nutr ESPEN. 2020;40:83\u20139.","journal-title":"Clin Nutr ESPEN"},{"key":"2796_CR44","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand O, Johnson J, Walter J, Atkinson L, Kline G, Frey A, et al. Symptoms and quality of life in patients with Fabry Disease: results from an International Patient Survey. Adv Ther. 2019;36:2866\u201380.","journal-title":"Adv Ther"},{"key":"2796_CR45","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","volume":"30","author":"AL Cole","year":"2007","unstructured":"Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007;30:943\u201351.","journal-title":"J Inherit Metab Dis"},{"key":"2796_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","volume":"37","author":"FE Bolsover","year":"2014","unstructured":"Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014;37:177\u201387.","journal-title":"J Inherit Metab Dis"},{"key":"2796_CR47","doi-asserted-by":"crossref","unstructured":"Ali N, Gillespie S, Laney D. Treatment of depression in adults with Fabry Disease. JIMD Rep. 2017; 13\u201321.","DOI":"10.1007\/8904_2017_21"},{"key":"2796_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jmd2.12240","volume":"62","author":"HK Pihlstr\u00f8m","year":"2021","unstructured":"Pihlstr\u00f8m HK, Weedon-Fekj\u00e6r MS, Bjerkely BL, Lippe C, \u00d8rstavik K, Mathisen P, et al. Health\u2010related quality of life in norwegian adults with Fabry disease: Disease severity, pain, fatigue and psychological distress. JIMD Rep. 2021;62:56\u201369.","journal-title":"JIMD Rep"},{"key":"2796_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10545-009-9025-6","volume":"33","author":"DA Laney","year":"2010","unstructured":"Laney DA, Gruskin DJ, Fernhoff PM, Cubells JF, Ousley OY, Hipp H, et al. Social-adaptive and psychological functioning of patients affected by Fabry disease. J Inherit Metab Dis. 2010;33:73\u201381.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02796-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:05:54Z","timestamp":1689926754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02796-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"KMS reports honoraria for speaking and\/or advisory boards from Sanofi and Takeda. AB has received consulting fees from Sanofi and Takeda. PBD has received consulting fees from Sanofi. DH has received honoraria for speaking and advisory boards, administered through UCL consultants, from Sanofi, Takeda, amicus, Freeline, Idorsia and Chiesi. AJ has received honoraria for participating in advisory boards for Sanofi, Amicus Therapeutics, Chiesi and Takeda, and research grant support from Amicus Therapeutics. LM has received honoraria as a speaker and educational support from Amicus, Sanofi and Takeda. AM has received honoraria and travel subsidence for participation in advisory panels for Amicus and Sanofi. UR has received honoraria for speaking or advisory boards from Amicus, Sanofi, Takeda and research grants from Amicus, Intrabio and Takeda. UR and AB participated in the advisory board meeting in 2021 run by Sanofi \u2013 \u201cUnderstanding how Fabry disease is managed in children in the current UK and Ireland clinical practice\u201d. Both report consultancy fees for this activity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Editorial assistance in the preparation of this manuscript was provided by Dr Robert Brines of Bite Medical Consulting. Funding for writing support was provided by Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing\/editorial assistance"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"203"}}